Nucleic Acid Therapeutics CDMO Market Size To Reach USD 12,613.8 Million In 2032

2025-06-11 09:08:16

(MENAFN- Market Press Release) June 10, 2025 10:49 am - The Nucleic Acid Therapeutics CDMO market, valued at USD 4,558.8 million in 2024, is expected to register robust revenue CAGR of 13.8%. Request free copy of this report:

June 10, 2025 - Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth. Nucleic acid treatments are part of the next generation of medications, which are now taking centre stage. Modalities such viral vectors, RNA forms, plasmids, CAR-T, and cell treatments are becoming more common in the early stages of therapeutic development.

On September 2024, ReciBioPharm, a leading advanced medicines CDMO services provider, and Hongene Biotech Corporation, a global leader in nucleic acid manufacturing, have established a strategic partnership to expand gene editing medication manufacturing capabilities. The two companies' strategic cooperation provides a one-of-a-kind solution for gene editing inventors. ReciBioPharm will broaden its service offering to include sgRNA manufacture, leveraging Hongene's novel synthesis technique to provide plasmid, mRNA, sgRNA, LNP, and fill-finish services in a single facility.

NA-based medications, such as gene replacement therapies, RNA therapeutics, and CRISPR gene editing, have demonstrated considerable promise in biological applications. Although this type of treatment is not yet widely available, the prospects for patients suffering from rare genetic illnesses are quite promising. Contrary to RNA therapeutics that have transient effect, CRISPR/Cas based treatments cannot be reversed if adverse events appear. Endosomal escape is an important aspect of NA-based drugs' therapeutic and pharmacological efficacy.

Want to Know What's Fueling the Nucleic Acid Therapeutics CDMO Market Growth? Get Exclusive Report Insights Here:

Segments market overview and growth Insights:
Based on the type, the Nucleic Acid Therapeutics CDMO market is segmented into oligonucleotide therapeutics, gene therapies, CRISPR and other gene editing technologies, plasmid DNA (pDNA) therapeutics, mRNA therapeutics, and others. The gene therapies segment held the largest market share in 2024. Nucleic acids are one of the most important sources not only for the understanding of the fundamental basis of human life but also for the development of a novel group of therapeutics. One of the significant advantages of DNA-based drugs over currently available low molecular weight pharmaceuticals is their selective recognition of molecular targets and pathways, which imparts tremendous specificity of action.

Regional market overview and growth insights:
North America held the largest market share in the Nucleic Acid Therapeutics CDMO market in 2024, driven by rising demand for nucleic acid-based therapies and advancements in manufacturing technologies. On April 2024, Exothera has launched a game-changing nucleic acids service offering driven by Ntensify, the world's first continuous-batch RNA synthesis platform. The Ntensify platform, developed by Exothera's sister business Quantoom Biosciences, accelerates the manufacturing of higher-quality, more cost-effective RNA therapies, providing considerable benefits at both small and large scale. It is also now available to biopharma businesses in North America for the first time, as Exothera broadens its reach beyond Europe.

Competitive Landscape and Key Competitors:
The Nucleic Acid Therapeutics CDMO market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the Nucleic Acid Therapeutics CDMO market report are:

oDanaher Corporation
oMerck KGaA
oAgilent Technologies, Inc
oThermo Fisher Scientific
oAGC Biologics
oKNC Laboratories Co., Ltd.
oLGC Limited
oWuxi AppTec
oSyngene International Limited
oBIOSPRING
oUnivercells Inc.
oExothera
oAsymchem Inc.
oAjinomoto Co., Inc.
oCuria Global, Inc.

Buy Your Exclusive Copy Now:

Major strategic developments by leading competitors:
etherna Immunotherapies NV: In January 2025, etherna Immunotherapies NV, a technological platform leader in mRNA and lipid-based nanoparticle (LNP) technologies, has announced a strategic agreement with Dropshot Therapeutics. The agreement brings together the cutting-edge platforms of both firms to accelerate the development of RNA-based medicines for the development of many novel drug candidates across several indications. Etherna will receive an upfront payment and research funds, as well as potential milestone payments during development and tiered royalties after product launch, totalling up to USD 950 million.

Stämm: On May 2024, Stämm and SuperMeat collaborated to accelerate cultivated meat biomanufacturing, with Varana Capital as a mutual investor. Stämm, an innovator in biopharma production, is expanding into food technology following good results with stem cell cultivation. They use their Bioprocessor, an automated continuous bubble-free bioreactor that provides exceptional cost reductions and 15x enhanced volumetric output in biologics production. The cooperation intends to improve muscle fiber growth, elongation, and fusing into mature muscle tissue while also increasing adipocyte synthesis to provide organic whole-cut portions.

Unlock the Key to Transforming Your Business Strategy with Our Nucleic Acid Therapeutics CDMO Market Insights –
.Download the report summary:
.Request customization:

Navistrat Analytics has segmented Nucleic Acid Therapeutics CDMO market based on type, service type, technology, and indication:
.Type Outlook (Revenue, USD Million; 2022-2032)
oOligonucleotide Therapeutics
a Oligonucleotides (ASOs)
b Interfering RNA (siRNA)
c (miRNA)
d
oGene Therapies
a gene therapies
b gene therapies
oCRISPR and Other Gene Editing CRISPR-Cas9
b Finger Nucleases (ZFNs)
c Activator-Like Effector Nucleases (TALENs)
oPlasmid DNA (pDNA) Therapeutics
omRNA Therapeutics
oOthers
.Service Type Outlook (Revenue, USD Million; 2022-2032)
oProcess Development
oManufacturing Services
oAnalytical & Quality Control Services
oOthers
.Technology Outlook (Revenue, USD Million; 2022-2032)
oSolid-Phase Synthesis
oEnzymatic Synthesis
oCell-Free Expression Systems
oViral Vector-Based Manufacturing
oNon-Viral Vector Manufacturing
oOthers
.Indication Outlook (Revenue, USD Million; 2022-2032)
oOncology
oRare Genetic Disorders
oInfectious Diseases
oNeurological Disorders
oOthers
.Regional Outlook (Revenue, USD Million; 2022-2032)
oNorth Benelux
g Countries
h of Europe
oAsia Pacific
a Japan
d Oceania
f Countries
g of APAC
oLatin Brazil
b of LATAM
oMiddle East & Africa
a Countries
b Turkey
e of MEA

Get a preview of the complete research study:

About Us:
At Navistrat Analytics, we provide high-quality, comprehensive syndicated and customized market research reports that deliver actionable insights and empower businesses through data-driven strategies. Choose Navistrat Analytics as your strategic growth partner for reliable market intelligence, and let us help you navigate the complexities of the market with clarity, precision, and confidence.

MENAFN11062025003520003262ID1109661177

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.